Vitrolife is committed to supporting successful treatment outcomes and has been dedicated to IVF since 1994, when the field was still young. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for fertility clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors. Our vision is to enable people to fulfil the dream of having a healthy baby), and we achieve this by supporting our customers in delivering successful treatment outcomes. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. We can help you maximise success. – Together. All the way. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.
